CD8A and melanoma: When administered in the form of DOX-loaded NPs to melanoma-bearing mice, the treatment substantially increased the number of mature DCs, CD8+ T cells, IFN-γ, and TNF-α while concurrently reducing Treg levels and down-regulating PD-L1 expression.